(VIANEWS) – Halozyme Therapeutics (HALO), Neurocrine Biosciences (NBIX), NICE Ltd (NICE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Halozyme Therapeutics (HALO)
31.8% sales growth and 146.7% return on equity
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $1.87.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 18.06. Meaning, the purchaser of the share is investing $18.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 146.7%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3.4%, now sitting on 780.71M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Halozyme Therapeutics’s EBITDA is 47.83.
2. Neurocrine Biosciences (NBIX)
24.6% sales growth and 10.77% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $1.9.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 73.56. Meaning, the purchaser of the share is investing $73.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.77%.
Sales Growth
Neurocrine Biosciences’s sales growth is 26% for the ongoing quarter and 24.6% for the next.
Volume
Today’s last reported volume for Neurocrine Biosciences is 1102700 which is 47.64% above its average volume of 746853.
Yearly Top and Bottom Value
Neurocrine Biosciences’s stock is valued at $139.77 at 10:22 EST, below its 52-week high of $143.35 and way higher than its 52-week low of $89.04.
Previous days news about Neurocrine Biosciences(NBIX)
- According to Zacks on Wednesday, 7 February, "For the quarter ended December 2023, Neurocrine Biosciences (NBIX Quick QuoteNBIX – Free Report) reported revenue of $515.2 million, up 25.1% over the same period last year. "
3. NICE Ltd (NICE)
12.7% sales growth and 10.65% return on equity
NICE Ltd., together with its subsidiaries, provides cloud platforms for AI-driven digital business solutions worldwide. It offers CXone, a cloud native open platform; Enlighten, an AI engine for CX that discovers automation opportunities for self-service; digital-entry points solutions that enable organizations to address consumers' needs; and journey orchestration solutions that empower organizations to connect and route customers to deal with the customer's request, and connects them using real time AI-based routing. The company also provides smart self service solutions that empower organizations to build intelligent automated conversations based on data; and prepared agent solutions and tools enable contact center agents to guide and alert them in real time; complete performance solutions that help organizations to record structured and unstructured customer interaction and transaction data; and NICE Evidencentral, an digital evidence management platform for public safety emergency communications, law enforcement, and criminal justice helps agencies. In addition, it offers X-Sight, is an open and flexible AI-cloud platform for financial crime and compliance; Xceed, a cloud platform for comprehensive AML and fraud prevention for small and mid-sized organizations; data intelligence solutions that enable organizations to turn raw data into comprehensive actionable intelligence to prevent and detect financial crimes; AI and analytics technologies to detect and prevent financial crimes in real-time; money laundering and fraud prevention solutions that help organizations adhere to capital markets compliance and anti-money laundering compliance regulations; intelligent investigations solutions; and self-service solutions that provide organizations with customization and self-development capabilities. The company was formerly known as NICE-Systems Ltd. and changed its name to NICE Ltd. in June 2016. NICE Ltd. was founded in 1986 and is based in Ra'anana, Israel.
Earnings Per Share
As for profitability, NICE Ltd has a trailing twelve months EPS of $4.93.
PE Ratio
NICE Ltd has a trailing twelve months price to earnings ratio of 44.77. Meaning, the purchaser of the share is investing $44.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.65%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 10.8% and 11.3%, respectively.
4. The Joint Corp. (JYNT)
5.8% sales growth and 6.15% return on equity
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
Earnings Per Share
As for profitability, The Joint Corp. has a trailing twelve months EPS of $0.18.
PE Ratio
The Joint Corp. has a trailing twelve months price to earnings ratio of 54.28. Meaning, the purchaser of the share is investing $54.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.15%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.4%, now sitting on 114.76M for the twelve trailing months.
Sales Growth
The Joint Corp.’s sales growth is 4.6% for the current quarter and 5.8% for the next.
Volume
Today’s last reported volume for The Joint Corp. is 49529 which is 56.96% below its average volume of 115093.
Moving Average
The Joint Corp.’s value is above its 50-day moving average of $9.22 and way below its 200-day moving average of $11.13.
5. CSG Systems International (CSGS)
5.7% sales growth and 24.38% return on equity
CSG Systems International, Inc. provides revenue management, customer experience, and payment solutions primarily to the communications industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers Advanced Convergent Platform, a private cloud-based platform; related customer communications management solutions, including field force automation, analytics, electronic bill presentment, ACH, etc. for processing voice, SMS/text, print, and e-mail messages; and cloud-based integrated suite of solutions for range of industries. The company also provides managed services; and professional services to implement, configure, and maintain its solutions, as well as licenses various solutions, such as mediation, partner management, rating, and charging. It serves financial services, healthcare, media and entertainment companies, and government markets. The company was incorporated in 1994 and is headquartered in Greenwood Village, Colorado.
Earnings Per Share
As for profitability, CSG Systems International has a trailing twelve months EPS of $2.4.
PE Ratio
CSG Systems International has a trailing twelve months price to earnings ratio of 21.73. Meaning, the purchaser of the share is investing $21.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.38%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5%, now sitting on 1.16B for the twelve trailing months.
